Brenner Alison T, Odebunmi Olufeyisayo O, Waters Austin R, Wangen Mary, Marciniak Macary W, Ferrari Renée M, Wheeler Stephanie B, Shah Parth D
University of North Carolina at Chapel Hill, Carrboro, NORTH CAROLINA, United States.
University of North Carolina at Chapel Hill, Chapel Hill, UT, United States.
Cancer Epidemiol Biomarkers Prev. 2025 Jul 30. doi: 10.1158/1055-9965.EPI-25-0275.
Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer (CRC) screening. It is not clear, however, whether community pharmacists are willing to incorporate CRC screening into their pharmacy practice, what potential drivers of willingness are, and, if unwilling, under what conditions pharmacists would be willing to provide PharmFIT™.
From September 2022 to January 2023, we surveyed 578 currently practicing community pharmacists. We assessed willingness to provide a pharmacy-based CRC screening program (PharmFIT™). We used multiple linear regression to identify correlates of perceived implementation complexity and multiple logistic regression to explore overall willingness to implement PharmFIT™ Results: Most pharmacists (80%) were willing to implement PharmFIT™. The most common reasons for unwillingness were that results needed to be reported to the patients' PCPs (52%), that appropriate training in delivering CRC screening be provided (48%) and that care coordination with PCPs be clear (46%). Perceived complexity of the intervention decreased as years in practice increased (β= 0.013; CI95%: 0.01-0.02) and as level of knowledge about CRC screening increased (β= 0.085; CI95%: 0.01-0.16). Respondents' willingness to implement PharmFIT™ increased as perceived complexity decreased (OR:5.68, CI95%: 3.96-8.15).
Most community pharmacists in the US would be willing to integrate PharmFIT™ into their current workflows. Training in how to deliver FIT and preparation for the coordination of test results and follow up care should be completed prior to implementing PharmFIT™.
Community pharmacies are a viable venue for delivering CRC screening.
可及性、不断扩大的执业范围以及迅速变化的政策环境，使美国社区药房成为结直肠癌（CRC）筛查的一个有前景的服务场所。然而，尚不清楚社区药剂师是否愿意将CRC筛查纳入其药房业务，愿意的潜在驱动因素是什么，以及如果不愿意，在何种情况下药剂师会愿意提供“药物适配性检测（PharmFIT™）”。
2022年9月至2023年1月，我们对578名在职社区药剂师进行了调查。我们评估了提供基于药房的CRC筛查项目（PharmFIT™）的意愿。我们使用多元线性回归来确定感知到的实施复杂性的相关因素，并使用多元逻辑回归来探索实施PharmFIT™的总体意愿。结果：大多数药剂师（80%）愿意实施PharmFIT™。不愿意的最常见原因是结果需要报告给患者的初级保健医生（PCP）（52%）、需要提供CRC筛查的适当培训（48%）以及与PCP的护理协调要明确（46%）。随着执业年限的增加（β = 0.013；95%置信区间：0.01 - 0.02）以及对CRC筛查知识水平的提高（β = 0.085；95%置信区间：0.01 - 0.16），干预的感知复杂性降低。随着感知复杂性的降低，受访者实施PharmFIT™的意愿增加（比值比：5.68，95%置信区间：3.96 - 8.15）。
美国大多数社区药剂师愿意将PharmFIT™整合到他们当前的工作流程中。在实施PharmFIT™之前，应完成关于如何进行粪便免疫化学检测（FIT）的培训以及检测结果协调和后续护理准备。
社区药房是提供CRC筛查的可行场所。
